Avenue Therapeutics, Inc. Stock price
Is Avenue Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Avenue Therapeutics, Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a Avenue Therapeutics, Inc. forecast:
Analyst Opinions
7 Analysts have issued a Avenue Therapeutics, Inc. forecast:
Don't miss a Thing! We will send you all news about Avenue Therapeutics, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Dr. Maclean |
| Employees | 2 |
| Founded | 2015 |
| Website | avenuetx.com |


